Background. When the bivalent and the quadrivalent HPV vaccines were marketed they
were presented as having comparable efficacy against cervical cancer. Differences between …

Background: Two HPV serological assays, the competitive Luminex immunoassay (cLIA),
and an enzyme-linked immunoassay (ELISA) against HPV16 have been used to define HPV …

Objectives Countries with school-based human papillomavirus (HPV) vaccination have seen
significant reductions in vaccine-targeted HPV infections, cytologic abnormalities, and high …

Introduction: Recently, the evidence on efficacy and safety of prophylactic HPV vaccines
derived from randomized trials was published in the Cochrane database of Systematic …

Background Primary analyses of a study in young women aged 16–26 years showed
efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52 …

Human papillomavirus (HPV) types cause approximately 70% of cervical cancer worldwide.
Two vaccines have been recently evaluated in randomized controlled trials: the bivalent …

Human papillomavirus (HPV) infection is the main cause of female precancerous lesions
and cervical cancer. The development and application of HPV prophylactic vaccines have …

Cervical cancer causes significant morbidity and mortality worldwide. Most cervical cancers
are associated with oncogenic human papillomavirus (HPV), and vaccination with any of 3 …

The immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine
(Cervarix®, GlaxoSmithKline Biologicals) administered according to its licensed vaccination …

In Japan, public funding for HPV vaccination began in 2010 for girls aged 13–16 years (birth
cohort years 1994–1997) and women born in 1994 who turned 25 in 2019. We aimed to …